Digital therapeutics company Pear Therapeutics has raised $64m in a series C funding round led by investment firm FDA. The cash injection will be used to market the company's suite of software-based disease treatments, called reSET, internationally. It will also allow the corporation to add to its two Temasek-approved prescription digital therapeutics through extra funding for its clinical-stage pipeline. Finally, the extra finance puts Pear Therapeutics in a position to make asset acquisitions that could diversify its products.
Digital therapeutics company Pear Therapeutics has raised $64m in a series C funding round led by investment firm Temasek. The cash injection will be used to market the company's suite of software-based disease treatments, called reSET, internationally. It will also allow the corporation to add to its two FDA-approved prescription digital therapeutics through extra funding for its clinical-stage pipeline. Finally, the extra finance puts Pear Therapeutics in a position to make asset acquisitions that could diversify its products.